

ASX ANNOUNCEMENT

Hepatitis C (TT-034) IND Application Update

Sydney, Australia, 6 January 2014: RNAi-based therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today announced that it had received, and agreed to, a request from the US Food and Drug Administration (USFDA) for a one week review extension of the company's Investigational New Drug (IND) application for the clinical trial of TT-034 (a ddRNAi-based therapeutic for treating Hepatitis C).

The reason for the extension is procedural and unrelated to the subject matter of the application.

The clinical trial process for TT-034 will be initiated after the 15 January 2014 (US time), provided the company can adequately answer any further questions the USFDA has regarding the IND application within the extension period. The company advises that it has already received and answered a number of minor technical queries from the USFDA in the past three weeks.

For more information please contact: Dr Peter French | Chief Executive Officer and Managing Director | Phone: +61 (02) 9555 6986 | pfrench@benitec.com | www.benitec.com

About TT-034: TT-034 is a potentially transformative therapeutic that is intended to provide a "one-shot-cure" for hepatitis C with a single injection. Preclinical studies have shown that the vector used to deliver TT-034 specifically targets liver cells where it transfects almost every cell without causing toxic effects. TT-034 is designed to prevent development of viral resistance, a major problem for most hepatitis C drugs, by simultaneously silencing three separate highly conserved regions on the virus genome. Animal studies have demonstrated that a single treatment of TT-034 is active out to 180 days (the duration of the studies).

About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.